Octapharma announces approval of new Nuwiq® product strengths in Europe, increasing dosing flexibility for patients with haemophilia A

Lachen, Switzerland 18 June 2018: Octapharma announced today that the European Medicines Agency...

Octapharma share promising preclinical data for SubQ-8, a novel subcutaneous recombinant FVIII, at WFH 2018

Lachen, Switzerland 28 May 2018: Octapharma announced today that pre-clinical data for SubQ-8 were p...


Octapharma’s success is the result of the combined contribution of all employees, what we call “the human factor”. To embark on a challenging and rewarding career in an innovative biopharmaceutical organization, explore our global opportunities